Digital Biomarkers Market By Type (Wearable, Mobile Application, Others), By Application (Cardiovascular Disease, Diabetes, Neurological Disorders, Respiratory Disease, Others), By Clinical Practice (Monitoring, Diagnostic, Prognostic), By End User (Healthcare Providers, Healthcare Consumers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
The digital biomarkers market was valued for $2,125.95 million in 2022 and is estimated to reach $14,678.40 million by 2032, exhibiting a CAGR of 21.3% from 2023 to 2032.
Digital biomarkers are characterized as measurable physiological and behavioral data that are obtained and assessed using digital devices such as portable, wearable, implantable, or ingestible ones. The information gathered is often used to forecast, affect, or explain outcomes connected to health. Digital biomarkers offer another chance to gather factual data that has therapeutic significance. This innovative open-access multidisciplinary approach unites informatics, engineering, biomedicine, regulatory science, and computer science.
The digital biomarkers market growth is driven by high presence of market players who manufacture digital biomarkers and increase in prevalence of chronic diseases such as cardiovascular diseases, respiratory diseases, psychiatric diseases, neurological diseases, and others. Digital biomarkers are used to monitor a wide range of diseases and health conditions. Digital biomarkers aim to monitor heart rate, heart rate variability, blood pressure, and other related parameters to assess the risk of cardiovascular diseases such as hypertension, arrhythmias, and heart failure. These biomarkers can be utilized to assess and monitor mental health conditions such as depression, anxiety, and bipolar disorder by analyzing patterns in sleep, activity levels, social interactions, and speech characteristics.
Moreover, digital biomarkers can aid in the monitoring and management of neurological conditions like Parkinson's disease, Alzheimer's disease, multiple sclerosis, and epilepsy. These biomarkers can include gait analysis, tremor frequency, cognitive performance, and sleep disturbances. Digital biomarkers can help track and analyze pain levels, activity patterns, sleep quality, and mood fluctuations in patients with chronic pain conditions, assisting in personalized pain management approaches.
For instance, according to the British Heart Foundation, in 2022, around 1,139,140 people were reported to have been suffering from heart and circulatory diseases in the UK. As per the same source, in 2022, around 650,681 male and 488,320 female population were suffering from heart and circulatory diseases in the UK. Thus, rise in number of chronic diseases is anticipated to drive the demand for digital biomarker and boost the growth of the market.
In addition, geriatric population is more susceptible to chronic diseases such as cardiovascular diseases, neurological disorders, respiratory diseases, and others. Thus, increase in the number of geriatric populations is expected to witness growth in prevalence of neurological diseases such as Alzheimer's dementia (AD). Therefore, this is expected to increase the demand for digital biomarkers and boost the growth of the market. According to World Health Organization, (WHO), population aged 60 years and over were expected to increase from 1 billion in 2020 to 1.4 billion in 2022 globally. By 2050, the global population of people aged 60 years and older is expected to increase by two-fold. The number of people aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.
Moreover, according to Alzheimer's Association, in 2022, an estimated 6.5 million Americans aged 65 and older were reported to have been living with Alzheimer's dementia (AD). This number is projected to grow to 13.8 million by 2060. On the other hand, data privacy and security concerns, and lack of awareness is anticipated to hamper the growth of the market. However, increase in demand for digital medical devices in the developed countries such as U.S., Canada, and Germany and growth opportunities in emerging markets are expected to create immense opportunities for the digital biomarkers market during the forecast period.
The digital biomarkers market is segmented on the basis of type, application, end user and region. By type the market is divided into wearable, mobile application, software, and others (sensor, card, and implantable). By application, the market is classified into cardiovascular disease, sleep & movement disease, neurological disorders, and others. (respiratory diseases, diabetes, psychiatric and musculoskeletal disorders). By clinical practice, the market is classified into monitoring, diagnostic and prognostic. By end user, the market is divided into healthcare companies, hospitals, and others (payers and patients)
Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the global digital biomarkers market are ActiGraph LLC, Verily Life Sciences, Alivecor, koneksahealth, Amgen, Brainomix, Feel Therapeutics, Sonde Health, Inc., Empatica, Clario. Key players operating in the market have adopted product approval, product launch, acquisition and agreement as their key strategies to expand their digital biomarkers market share.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the digital biomarkers market analysis from 2022 to 2032 to identify the prevailing digital biomarkers market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the digital biomarkers market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global digital biomarkers market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Wearable
Mobile Application
Others
By Application
Neurological Disorders
Respiratory Disease
Others
Cardiovascular Disease
Diabetes
By Clinical Practice
Monitoring
Diagnostic
Prognostic
By End User
Healthcare Providers
Healthcare Consumers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa,
Saudi Arabia
Rest of LAMEA
Key Market Players
ActiGraph LLC
AliveCor
Amgen Inc.
Brainomix
Clario
Empatica
Feel Therapeutics
Koneksahealth
Sonde Health, Inc.
Verily Life Sciences LLC
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of chronic diseases
- 3.4.1.2. Increase in number of geriatric populations
- 3.4.1.3. Benefits associated with digital biomarkers
- 3.4.2. Restraints
- 3.4.2.1. Data security issue
- 3.4.3. Opportunities
- 3.4.3.1. Rise in number of product approvals and products launches by market players.
- 3.4.3.2. High presence of market players
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: DIGITAL BIOMARKERS MARKET, BY TYPE
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Wearable
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Mobile Application
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- CHAPTER 5: DIGITAL BIOMARKERS MARKET, BY APPLICATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Cardiovascular Disease
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Diabetes
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Neurological Disorders
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- 5.5. Respiratory Disease
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
- 5.6. Others
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
- CHAPTER 6: DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Monitoring
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Diagnostic
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Prognostic
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: DIGITAL BIOMARKERS MARKET, BY END USER
- 7.1. Overview
- 7.1.1. Market size and forecast
- 7.2. Healthcare Providers
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
- 7.3. Healthcare Consumers
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
- 7.4. Others
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country
- CHAPTER 8: DIGITAL BIOMARKERS MARKET, BY REGION
- 8.1. Overview
- 8.1.1. Market size and forecast By Region
- 8.2. North America
- 8.2.1. Key trends and opportunities
- 8.2.2. Market size and forecast, by Type
- 8.2.3. Market size and forecast, by Application
- 8.2.4. Market size and forecast, by Clinical Practice
- 8.2.5. Market size and forecast, by End User
- 8.2.6. Market size and forecast, by country
- 8.2.6.1. U.S.
- 8.2.6.1.1. Key market trends, growth factors and opportunities
- 8.2.6.1.2. Market size and forecast, by Type
- 8.2.6.1.3. Market size and forecast, by Application
- 8.2.6.1.4. Market size and forecast, by Clinical Practice
- 8.2.6.1.5. Market size and forecast, by End User
- 8.2.6.2. Canada
- 8.2.6.2.1. Key market trends, growth factors and opportunities
- 8.2.6.2.2. Market size and forecast, by Type
- 8.2.6.2.3. Market size and forecast, by Application
- 8.2.6.2.4. Market size and forecast, by Clinical Practice
- 8.2.6.2.5. Market size and forecast, by End User
- 8.2.6.3. Mexico
- 8.2.6.3.1. Key market trends, growth factors and opportunities
- 8.2.6.3.2. Market size and forecast, by Type
- 8.2.6.3.3. Market size and forecast, by Application
- 8.2.6.3.4. Market size and forecast, by Clinical Practice
- 8.2.6.3.5. Market size and forecast, by End User
- 8.3. Europe
- 8.3.1. Key trends and opportunities
- 8.3.2. Market size and forecast, by Type
- 8.3.3. Market size and forecast, by Application
- 8.3.4. Market size and forecast, by Clinical Practice
- 8.3.5. Market size and forecast, by End User
- 8.3.6. Market size and forecast, by country
- 8.3.6.1. Germany
- 8.3.6.1.1. Key market trends, growth factors and opportunities
- 8.3.6.1.2. Market size and forecast, by Type
- 8.3.6.1.3. Market size and forecast, by Application
- 8.3.6.1.4. Market size and forecast, by Clinical Practice
- 8.3.6.1.5. Market size and forecast, by End User
- 8.3.6.2. France
- 8.3.6.2.1. Key market trends, growth factors and opportunities
- 8.3.6.2.2. Market size and forecast, by Type
- 8.3.6.2.3. Market size and forecast, by Application
- 8.3.6.2.4. Market size and forecast, by Clinical Practice
- 8.3.6.2.5. Market size and forecast, by End User
- 8.3.6.3. UK
- 8.3.6.3.1. Key market trends, growth factors and opportunities
- 8.3.6.3.2. Market size and forecast, by Type
- 8.3.6.3.3. Market size and forecast, by Application
- 8.3.6.3.4. Market size and forecast, by Clinical Practice
- 8.3.6.3.5. Market size and forecast, by End User
- 8.3.6.4. Italy
- 8.3.6.4.1. Key market trends, growth factors and opportunities
- 8.3.6.4.2. Market size and forecast, by Type
- 8.3.6.4.3. Market size and forecast, by Application
- 8.3.6.4.4. Market size and forecast, by Clinical Practice
- 8.3.6.4.5. Market size and forecast, by End User
- 8.3.6.5. Spain
- 8.3.6.5.1. Key market trends, growth factors and opportunities
- 8.3.6.5.2. Market size and forecast, by Type
- 8.3.6.5.3. Market size and forecast, by Application
- 8.3.6.5.4. Market size and forecast, by Clinical Practice
- 8.3.6.5.5. Market size and forecast, by End User
- 8.3.6.6. Rest of Europe
- 8.3.6.6.1. Key market trends, growth factors and opportunities
- 8.3.6.6.2. Market size and forecast, by Type
- 8.3.6.6.3. Market size and forecast, by Application
- 8.3.6.6.4. Market size and forecast, by Clinical Practice
- 8.3.6.6.5. Market size and forecast, by End User
- 8.4. Asia-Pacific
- 8.4.1. Key trends and opportunities
- 8.4.2. Market size and forecast, by Type
- 8.4.3. Market size and forecast, by Application
- 8.4.4. Market size and forecast, by Clinical Practice
- 8.4.5. Market size and forecast, by End User
- 8.4.6. Market size and forecast, by country
- 8.4.6.1. Japan
- 8.4.6.1.1. Key market trends, growth factors and opportunities
- 8.4.6.1.2. Market size and forecast, by Type
- 8.4.6.1.3. Market size and forecast, by Application
- 8.4.6.1.4. Market size and forecast, by Clinical Practice
- 8.4.6.1.5. Market size and forecast, by End User
- 8.4.6.2. China
- 8.4.6.2.1. Key market trends, growth factors and opportunities
- 8.4.6.2.2. Market size and forecast, by Type
- 8.4.6.2.3. Market size and forecast, by Application
- 8.4.6.2.4. Market size and forecast, by Clinical Practice
- 8.4.6.2.5. Market size and forecast, by End User
- 8.4.6.3. India
- 8.4.6.3.1. Key market trends, growth factors and opportunities
- 8.4.6.3.2. Market size and forecast, by Type
- 8.4.6.3.3. Market size and forecast, by Application
- 8.4.6.3.4. Market size and forecast, by Clinical Practice
- 8.4.6.3.5. Market size and forecast, by End User
- 8.4.6.4. Australia
- 8.4.6.4.1. Key market trends, growth factors and opportunities
- 8.4.6.4.2. Market size and forecast, by Type
- 8.4.6.4.3. Market size and forecast, by Application
- 8.4.6.4.4. Market size and forecast, by Clinical Practice
- 8.4.6.4.5. Market size and forecast, by End User
- 8.4.6.5. South Korea
- 8.4.6.5.1. Key market trends, growth factors and opportunities
- 8.4.6.5.2. Market size and forecast, by Type
- 8.4.6.5.3. Market size and forecast, by Application
- 8.4.6.5.4. Market size and forecast, by Clinical Practice
- 8.4.6.5.5. Market size and forecast, by End User
- 8.4.6.6. Rest of Asia-Pacific
- 8.4.6.6.1. Key market trends, growth factors and opportunities
- 8.4.6.6.2. Market size and forecast, by Type
- 8.4.6.6.3. Market size and forecast, by Application
- 8.4.6.6.4. Market size and forecast, by Clinical Practice
- 8.4.6.6.5. Market size and forecast, by End User
- 8.5. LAMEA
- 8.5.1. Key trends and opportunities
- 8.5.2. Market size and forecast, by Type
- 8.5.3. Market size and forecast, by Application
- 8.5.4. Market size and forecast, by Clinical Practice
- 8.5.5. Market size and forecast, by End User
- 8.5.6. Market size and forecast, by country
- 8.5.6.1. Brazil
- 8.5.6.1.1. Key market trends, growth factors and opportunities
- 8.5.6.1.2. Market size and forecast, by Type
- 8.5.6.1.3. Market size and forecast, by Application
- 8.5.6.1.4. Market size and forecast, by Clinical Practice
- 8.5.6.1.5. Market size and forecast, by End User
- 8.5.6.2. South Africa,
- 8.5.6.2.1. Key market trends, growth factors and opportunities
- 8.5.6.2.2. Market size and forecast, by Type
- 8.5.6.2.3. Market size and forecast, by Application
- 8.5.6.2.4. Market size and forecast, by Clinical Practice
- 8.5.6.2.5. Market size and forecast, by End User
- 8.5.6.3. Saudi Arabia
- 8.5.6.3.1. Key market trends, growth factors and opportunities
- 8.5.6.3.2. Market size and forecast, by Type
- 8.5.6.3.3. Market size and forecast, by Application
- 8.5.6.3.4. Market size and forecast, by Clinical Practice
- 8.5.6.3.5. Market size and forecast, by End User
- 8.5.6.4. Rest of LAMEA
- 8.5.6.4.1. Key market trends, growth factors and opportunities
- 8.5.6.4.2. Market size and forecast, by Type
- 8.5.6.4.3. Market size and forecast, by Application
- 8.5.6.4.4. Market size and forecast, by Clinical Practice
- 8.5.6.4.5. Market size and forecast, by End User
- CHAPTER 9: COMPETITIVE LANDSCAPE
- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top player positioning, 2022
- CHAPTER 10: COMPANY PROFILES
- 10.1. ActiGraph LLC
- 10.1.1. Company overview
- 10.1.2. Key Executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Key strategic moves and developments
- 10.2. Verily Life Sciences LLC
- 10.2.1. Company overview
- 10.2.2. Key Executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.3. AliveCor
- 10.3.1. Company overview
- 10.3.2. Key Executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Key strategic moves and developments
- 10.4. Koneksahealth
- 10.4.1. Company overview
- 10.4.2. Key Executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.6. Key strategic moves and developments
- 10.5. Amgen Inc.
- 10.5.1. Company overview
- 10.5.2. Key Executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
- 10.5.6. Business performance
- 10.6. Empatica
- 10.6.1. Company overview
- 10.6.2. Key Executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Key strategic moves and developments
- 10.7. Sonde Health, Inc.
- 10.7.1. Company overview
- 10.7.2. Key Executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
- 10.8. Clario
- 10.8.1. Company overview
- 10.8.2. Key Executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
- 10.9. Feel Therapeutics
- 10.9.1. Company overview
- 10.9.2. Key Executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.9.6. Key strategic moves and developments
- 10.10. Brainomix
- 10.10.1. Company overview
- 10.10.2. Key Executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- LIST OF TABLES
- TABLE 01. GLOBAL DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 02. DIGITAL BIOMARKERS MARKET FOR WEARABLE, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. DIGITAL BIOMARKERS MARKET FOR MOBILE APPLICATION, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. DIGITAL BIOMARKERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 05. GLOBAL DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 06. DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. DIGITAL BIOMARKERS MARKET FOR DIABETES, BY REGION, 2022-2032 ($MILLION)
- TABLE 08. DIGITAL BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 09. DIGITAL BIOMARKERS MARKET FOR RESPIRATORY DISEASE, BY REGION, 2022-2032 ($MILLION)
- TABLE 10. DIGITAL BIOMARKERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. GLOBAL DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 12. DIGITAL BIOMARKERS MARKET FOR MONITORING, BY REGION, 2022-2032 ($MILLION)
- TABLE 13. DIGITAL BIOMARKERS MARKET FOR DIAGNOSTIC, BY REGION, 2022-2032 ($MILLION)
- TABLE 14. DIGITAL BIOMARKERS MARKET FOR PROGNOSTIC, BY REGION, 2022-2032 ($MILLION)
- TABLE 15. GLOBAL DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 16. DIGITAL BIOMARKERS MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 17. DIGITAL BIOMARKERS MARKET FOR HEALTHCARE CONSUMERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 18. DIGITAL BIOMARKERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 19. DIGITAL BIOMARKERS MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 20. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 21. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 22. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 23. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 24. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 25. U.S. DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 26. U.S. DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 27. U.S. DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 28. U.S. DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 29. CANADA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 30. CANADA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 31. CANADA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 32. CANADA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 33. MEXICO DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 34. MEXICO DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 35. MEXICO DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 36. MEXICO DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 37. EUROPE DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 38. EUROPE DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 39. EUROPE DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 40. EUROPE DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 41. EUROPE DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 42. GERMANY DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 43. GERMANY DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 44. GERMANY DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 45. GERMANY DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 46. FRANCE DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 47. FRANCE DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 48. FRANCE DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 49. FRANCE DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 50. UK DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 51. UK DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 52. UK DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 53. UK DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 54. ITALY DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 55. ITALY DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 56. ITALY DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 57. ITALY DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 58. SPAIN DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 59. SPAIN DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 60. SPAIN DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 61. SPAIN DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 62. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 63. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 64. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 65. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 66. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 67. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 68. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 69. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 70. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 71. JAPAN DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 72. JAPAN DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 73. JAPAN DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 74. JAPAN DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 75. CHINA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 76. CHINA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 77. CHINA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 78. CHINA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 79. INDIA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 80. INDIA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 81. INDIA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 82. INDIA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 83. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 84. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 85. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 86. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 87. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 88. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 89. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 90. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 91. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 92. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 93. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 94. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 95. LAMEA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 96. LAMEA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 97. LAMEA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 98. LAMEA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 99. LAMEA DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 100. BRAZIL DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 101. BRAZIL DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 102. BRAZIL DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 103. BRAZIL DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 104. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 105. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 106. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 107. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 108. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 109. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 110. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 111. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 112. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 113. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 114. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
- TABLE 115. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 116. ACTIGRAPH LLC: KEY EXECUTIVES
- TABLE 117. ACTIGRAPH LLC: COMPANY SNAPSHOT
- TABLE 118. ACTIGRAPH LLC: PRODUCT SEGMENTS
- TABLE 119. ACTIGRAPH LLC: SERVICE SEGMENTS
- TABLE 120. ACTIGRAPH LLC: PRODUCT PORTFOLIO
- TABLE 121. ACTIGRAPH LLC: KEY STRATERGIES
- TABLE 122. VERILY LIFE SCIENCES LLC: KEY EXECUTIVES
- TABLE 123. VERILY LIFE SCIENCES LLC: COMPANY SNAPSHOT
- TABLE 124. VERILY LIFE SCIENCES LLC: PRODUCT SEGMENTS
- TABLE 125. VERILY LIFE SCIENCES LLC: PRODUCT PORTFOLIO
- TABLE 126. ALIVECOR: KEY EXECUTIVES
- TABLE 127. ALIVECOR: COMPANY SNAPSHOT
- TABLE 128. ALIVECOR: PRODUCT SEGMENTS
- TABLE 129. ALIVECOR: SERVICE SEGMENTS
- TABLE 130. ALIVECOR: PRODUCT PORTFOLIO
- TABLE 131. ALIVECOR: KEY STRATERGIES
- TABLE 132. KONEKSAHEALTH: KEY EXECUTIVES
- TABLE 133. KONEKSAHEALTH: COMPANY SNAPSHOT
- TABLE 134. KONEKSAHEALTH: PRODUCT SEGMENTS
- TABLE 135. KONEKSAHEALTH: PRODUCT PORTFOLIO
- TABLE 136. KONEKSAHEALTH: KEY STRATERGIES
- TABLE 137. AMGEN INC.: KEY EXECUTIVES
- TABLE 138. AMGEN INC.: COMPANY SNAPSHOT
- TABLE 139. AMGEN INC.: PRODUCT SEGMENTS
- TABLE 140. AMGEN INC.: PRODUCT PORTFOLIO
- TABLE 141. EMPATICA: KEY EXECUTIVES
- TABLE 142. EMPATICA: COMPANY SNAPSHOT
- TABLE 143. EMPATICA: PRODUCT SEGMENTS
- TABLE 144. EMPATICA: PRODUCT PORTFOLIO
- TABLE 145. EMPATICA: KEY STRATERGIES
- TABLE 146. SONDE HEALTH, INC.: KEY EXECUTIVES
- TABLE 147. SONDE HEALTH, INC.: COMPANY SNAPSHOT
- TABLE 148. SONDE HEALTH, INC.: PRODUCT SEGMENTS
- TABLE 149. SONDE HEALTH, INC.: PRODUCT PORTFOLIO
- TABLE 150. CLARIO: KEY EXECUTIVES
- TABLE 151. CLARIO: COMPANY SNAPSHOT
- TABLE 152. CLARIO: PRODUCT SEGMENTS
- TABLE 153. CLARIO: PRODUCT PORTFOLIO
- TABLE 154. FEEL THERAPEUTICS: KEY EXECUTIVES
- TABLE 155. FEEL THERAPEUTICS: COMPANY SNAPSHOT
- TABLE 156. FEEL THERAPEUTICS: PRODUCT SEGMENTS
- TABLE 157. FEEL THERAPEUTICS: PRODUCT PORTFOLIO
- TABLE 158. FEEL THERAPEUTICS: KEY STRATERGIES
- TABLE 159. BRAINOMIX: KEY EXECUTIVES
- TABLE 160. BRAINOMIX: COMPANY SNAPSHOT
- TABLE 161. BRAINOMIX: PRODUCT SEGMENTS
- TABLE 162. BRAINOMIX: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. DIGITAL BIOMARKERS MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF DIGITAL BIOMARKERS MARKET, 2022-2032
- FIGURE 03. DIGITAL BIOMARKERS MARKET,2022-2032
- FIGURE 04. TOP INVESTMENT POCKETS IN DIGITAL BIOMARKERS MARKET (2023-2032)
- FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 06. LOW THREAT OF NEW ENTRANTS
- FIGURE 07. LOW THREAT OF SUBSTITUTES
- FIGURE 08. LOW INTENSITY OF RIVALRY
- FIGURE 09. LOW BARGAINING POWER OF BUYERS
- FIGURE 10. GLOBAL DIGITAL BIOMARKERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. DIGITAL BIOMARKERS MARKET, BY TYPE, 2022(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR WEARABLE, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR MOBILE APPLICATION, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 15. DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR DIABETES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR RESPIRATORY DISEASE, BY COUNTRY 2022 AND 2032(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022(%)
- FIGURE 22. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR MONITORING, BY COUNTRY 2022 AND 2032(%)
- FIGURE 23. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR DIAGNOSTIC, BY COUNTRY 2022 AND 2032(%)
- FIGURE 24. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR PROGNOSTIC, BY COUNTRY 2022 AND 2032(%)
- FIGURE 25. DIGITAL BIOMARKERS MARKET, BY END USER, 2022(%)
- FIGURE 26. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 27. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR HEALTHCARE CONSUMERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 28. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 29. DIGITAL BIOMARKERS MARKET BY REGION, 2022(%)
- FIGURE 30. U.S. DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 31. CANADA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 32. MEXICO DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 33. GERMANY DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 34. FRANCE DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 35. UK DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 36. ITALY DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 37. SPAIN DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 38. REST OF EUROPE DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 39. JAPAN DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 40. CHINA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 41. INDIA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 42. AUSTRALIA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 43. SOUTH KOREA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 44. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 45. BRAZIL DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 46. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 47. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 48. REST OF LAMEA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
- FIGURE 49. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 53. COMPETITIVE DASHBOARD
- FIGURE 54. COMPETITIVE HEATMAP: DIGITAL BIOMARKERS MARKET
- FIGURE 55. TOP PLAYER POSITIONING, 2022
- FIGURE 56. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 57. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 58. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook